213
IRUS Total
Downloads
  Altmetric

Effects of SGLT2 inhibitors in type 2 diabetes, comparing women to men

File Description SizeFormat 
Effects of SGLT2 inhibitors in type 2 diabetes, comparing women to men_Aug 2019.pdfAccepted version509.04 kBAdobe PDFView/Open
Title: Effects of SGLT2 inhibitors in type 2 diabetes, comparing women to men
Authors: Rådholm, K
Zhou, Z
Clemens, K
Neal, B
Woodward, M
Item Type: Journal Article
Abstract: AIM: Sodium glucose cotransporter 2 (SGLT2) inhibitors prevent cardiovascular complications in type 2 diabetes. We aimed to study whether they have similar effects in women and men. METHODS: We summarised the effects of SGLT2 compared to placebo on vascular and safety outcomes by sex. We included patients with type 2 diabetes enrolled in the EMPA-REG OUTCOME, CANVAS Program, DECLARE TIMI-58 and CREDENCE trials. RESULTS: There were no sex differences in the risk ratios, SGLT2 versus control, for vascular efficacy outcomes or death (all p interaction ≥ 0.12) with clear protection against major adverse cardiovascular events, heart failure, vascular death and total mortality. SGLT2 inhibitor treatment was also associated with comparable relative risks in women and men for the safety outcomes of amputation, fracture, genital infection and urinary tract infection (all p interaction ≥ 0.17). CONCLUSION: SGLT2 inhibition provided comparable protection against vascular risks and death, and similar risks of serious adverse events, for women and men. This article is protected by copyright. All rights reserved.
Issue Date: Feb-2020
Date of Acceptance: 29-Aug-2019
URI: http://hdl.handle.net/10044/1/73345
DOI: 10.1111/dom.13876
ISSN: 1462-8902
Publisher: Wiley
Start Page: 263
End Page: 266
Journal / Book Title: Diabetes, Obesity and Metabolism: a journal of pharmacology and therapeutics
Volume: 22
Issue: 2
Copyright Statement: © 2019 John Wiley & Sons Ltd. This is the accepted version of the following article: Rådholm, K, Zhou, Z, Clemens, K, Neal, B, Woodward, M. Effects of sodium‐glucose co‐transporter‐2 inhibitors in type 2 diabetes in women versus men. Diabetes Obes Metab. 2020; 22: 263– 266, which has been published in final form at https://doi.org/10.1111/dom.13876
Keywords: Science & Technology
Life Sciences & Biomedicine
Endocrinology & Metabolism
canagliflozin
dapagliflozin
empagliflozin
meta-analysis
SGLT2 inhibitor
type 2 diabetes
EMPAGLIFLOZIN
SGLT2 inhibitor
canagliflozin
dapagliflozin
empagliflozin
meta-analysis
type 2 diabetes
1103 Clinical Sciences
Endocrinology & Metabolism
Publication Status: Published online
Conference Place: England
Online Publication Date: 2019-09-04
Appears in Collections:School of Public Health